Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
clinical trials
life sciences
national blog main
raleigh-durham blog main
4
×
raleigh-durham top stories
amgen
boston blog main
eli lilly
fda
indiana blog main
indiana top stories
migraine research foundation
new york blog main
new york top stories
san francisco blog main
san francisco top stories
teva pharmaceutical
boston top stories
boulder/denver blog main
boulder/denver top stories
calcitonin gene-related peptide
chronic migraine
detroit blog main
detroit top stories
eptinezumab
erenumab
fremanezumab
galcanezumab
impel neuropharma
lasmiditan
medical device
migraine
national
national top stories
san diego blog main
san diego top stories
seattle blog main
seattle top stories
texas blog main
What
drug
migraine
4
×
approval
fda
new
won
class
companies
decades
activity
acute
addresses
amgen
arguments
big
biotech
candidates
causes
commercialized
competitors
condition
days
developed
dog
drugs
eli
firm
friday
gets
giant
giving
hasn’t
head
ipo
ipos
lasmiditan
leading
lilly
lilly’s
line
Language
unset
Current search:
migraine
×
" raleigh-durham blog main "
×
@xconomy.com
4 years ago
FDA OKs Lilly’s Lasmiditan, First New Acute Migraine Drug in Decades
@xconomy.com
4 years ago
Pfizer Spinout SpringWorks, Migraine Drug Firm Satsuma Prep IPOs
@xconomy.com
5 years ago
At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments
@xconomy.com
5 years ago
Amgen Migraine Drug Gets FDA Nod, First in New Class of Medicines